Koteze, Sokola 1 st., 83-200 Starogard Gdanski, Poland
Phone/Fax: (+48) 58 531 02 59
Phone: (+48) 606 93 82 51

Brexit and EU rules for medicinal products for human use and veterinary medicinal products

  • 7 March 2019
  • API, batch release, Brexit, CP, EC, EMA, finished product, GMP, impact, import, legal consequences, MA, MAH, manufacture, marketing authorisation, marketing authorisation holder, medicinal products, notice, QPPV, ratification, RMS, site, transfer, transition period, UK's withdrawal, variation, Withdrawal Agreement,

ASE Pharma Solutions


DO NOT RELY ON THE TRANSITION PERIOD!


 

Brexit and law

In view of the uncertainties surrounding the ratification of the Withdrawal Agreement, all interested parties, and especially economic operators, are reminded of legal repercussions, which need to be considered when the United Kingdom becomes a third country.

The European Commission have published revised versions of Notice to stakeholders and Questions and Answers (Q&As) documents in 22 official EU languages.


Brexit no deal

 

The list of Questions and Answers (Q&As) complements the Notice to stakeholders and addresses a situation where the United Kingdom becomes a third country on 30 March 2019 (“the withdrawal date”) without a withdrawal agreement and hence without a transition period provided for in the draft Withdrawal Agreement.


DO NOT RELY ON THE TRANSITION PERIOD!


 
DOCUMENTS:
 
EC/EMA 

 


 

DO NOT RELY ON THE TRANSITION PERIOD!


 
 
Sources: EC, EMA
 

Related entries:

Brexit and EU rules for batch testing of medicinal products

Brexit and EU rules in the field of clinical trials (CTs)

Pharmaceutical industry Brexit preparedness and its legal consequences for MAH